Pseudomonas aeruginosa: Difference between revisions
From IDWiki
Pseudomonas aeruginosa
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
| − | == |
+ | == Background == |
| + | === Microbiology === |
||
| − | |||
| − | * Oxidase-positive, non-fermenting Gram negative bacillus |
+ | * [[Has oxidase test::Oxidase-positive]], non-fermenting [[Has Gram stain::Gram-negative]] [[Has cell shape::bacillus]] |
| − | |||
| ⚫ | |||
| ⚫ | |||
* Broad intrinsic and acquired antibiotic resistance |
* Broad intrinsic and acquired antibiotic resistance |
||
* Membrane impermeability |
* Membrane impermeability |
||
| Line 12: | Line 11: | ||
* Plasmid sharing |
* Plasmid sharing |
||
| + | === Epidemiology === |
||
| − | == Environment and Infections == |
||
| − | |||
* Loves moist and wet environments |
* Loves moist and wet environments |
||
* Causes healthcare-associated infections |
* Causes healthcare-associated infections |
||
Revision as of 11:05, 24 October 2019
Background
Microbiology
- Oxidase-positive, non-fermenting Gram-negative bacillus
Mechanisms of Resistance
- Broad intrinsic and acquired antibiotic resistance
- Membrane impermeability
- MexAB-OprM efflux pump
- Acquired mutations
- Inducible AmpC β-lactamase
- Plasmid sharing
Epidemiology
- Loves moist and wet environments
- Causes healthcare-associated infections
- UTI, SSI, bacteremia, HAP, VAP
- Especially common in cystic fibrosis
Treatment
- See Antipseudomonal antibiotics
- Double coverage (ß-lactam + non-ß-lactam) in cases of severe infection in order to ensure activity against the infection
References
- ^ D. M. Livermore. Multiple Mechanisms of Antimicrobial Resistance in Pseudomonas aeruginosa: Our Worst Nightmare?. Clinical Infectious Diseases. 2002;34(5):634-640. doi:10.1086/338782.
